Trident Lifeline Limited

Healthcare — Pharmaceutical Retailers · BSE

₹422.00+₹8.25 (+1.99%)

DalalBaazaar Score

68 / 100

🟢 Good

Verdict

REASONABLE

Risk

Moderate

Driven by negative free cash flow, micro-cap size, which brings thin liquidity.

In simple words: Strong business and financial position, with both sales and profits growing well. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:44 pm

Understanding the Business

Company site ↗

The 60-second version of Trident Lifeline Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally.

IndustryPharmaceutical Retailers

SectorHealthcare

Employees46

Annual revenue₹129 Cr

How does it make money?

Turns over ₹129 Cr a year. Of every ₹100 of sales, about ₹15 reaches shareholders as profit, with ₹26 left at the operating level before interest, tax and depreciation. Each of its 46 employees supports ₹2.80 Cr of revenue a year, the signature of a capital- or asset-led business.

Revenue / employee₹2.80 Cr

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, DR. REDDY S LABORATORIES, CIPLA LTD, DIVI S LABORATORIES LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Some evidence

ROCE of 21.8% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

Peer median ROE14.5%

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +307% while net margin moved -22% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+307%

Margin effect-22%

DalalBaazaar Score

68/ 100

Good

Weighted across six categories. Every point is explained below.

✓ Beta of -0.32 — historically steadier than the index
✗ Micro Cap: thinner liquidity and sharper drawdowns are normal
✗ Trading within 10% of its 52-week high — entries here carry more pullback risk
✗ Negative free cash flow means dependence on external funding

Quality vs. Valuation

Company Quality

73/ 100

Good

How good the business is, ignoring the share price entirely.

Valuation

71/ 100

Cheap

What you are being asked to pay, ignoring how good the business is.

A good business currently available at an undemanding price — the combination this framework is built to look for.

Historical Valuation

Current P/E

23.9x

3Y Median

30.4x

40 monthly readings · mean 35.4x · range 16.7x–58.9x

Sector Median

33.3x

median of 4 sector peers

🟢Current valuation is approximately 22% below its 3y median of 30.4x. Cheaper than its own history, which is worth a reason too: the market may be pricing in something the backward-looking numbers do not show.

🟢Against its sector it trades 28% below the peer median of 33.3x.

vs. its own history

Cheap

30.4x median over 40 months · -22%

vs. sector peers

Cheap

33.3x median of 4 peers · -28%

vs. generic bands

Fair

15x–35x

EV/EBITDA

16.8x

PEG

0.51

What's Good / What's Bad

🟢 What's Going Well5

Margins are improving
EBITDA margin is up from 24.0% to 26.4% over 3 years.
Return on equity is rising
ROE has improved from 13.2% to 19.0%.
Return on capital is rising
ROCE has improved from 13.6% to 21.8%.
High return on capital employed
ROCE of 21.8% is the mark of a business that converts capital into profit efficiently.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

4 items require attention · 4 high

🔴Debt has risen sharplyFinancial
Total debt is up 849% over 3 years, from ₹8 Cr to ₹73 Cr.
🔴Free cash flow negative for 4 yearsFinancial
The business has not covered its capital spending from operations for several years running, which has to be funded externally.
🔴Receivables growing faster than salesFinancial
Receivables up 509% against revenue up 307% — sales are being booked faster than they are collected.
🔴Inventory building faster than salesFinancial
Inventory up 408% against revenue up 307% — stock may not be moving.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Capital compounds at a high rate
ROCE of 21.8% means each rupee reinvested earns well above what capital costs. If the company can keep deploying at this rate, growth creates value rather than just consuming cash.
Margin expansion has further to run
EBITDA margin has risen from 24.0% to 26.4%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Priced below its own history
The stock trades 22% below its own median multiple. If the business performs as it has and simply re-rates back to normal, that gap is return on its own.
Cheaper than its peers
It trades 28% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Sales are being booked faster than collected
Receivables are up 509% against revenue up 307%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
4 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 45% a year✓ 59.7% CAGR
Latest reported year was 42.8%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 24%✓ 26.4%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Debt / EBITDA stays below 2x✗ 2.1x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
4Free cash flow remains positive✗ -₹32 Cr
Profit that never becomes cash eventually stops being profit.
5ROCE stays above 19%✓ 21.8%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

9 / 11 checks passed

✓ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✗ Not buying right at the 52-week high
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

5 good · 4 neutral · 2 weak

Market Cap

₹505 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

23.9x

Fair

Fairly valued against the generic band

P/B Ratio

5.01x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹17.67

Profitable

Profitable on a per-share basis

ROE

19.0%

Strong

Strong capital efficiency

ROCE

21.8%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.68x

Moderate

Moderate leverage

Revenue Growth (YoY)

42.8%

Healthy

Healthy top-line growth

Profit Growth (YoY)

62.1%

Healthy

Profits growing at a healthy clip

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

-₹32 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

Operating Margin

20.4%

Good

Healthy core-business profitability

Net Margin

15.1%

Good

Strong bottom-line conversion

Current Ratio

1.59

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

-0.32

Defensive

Steadier than the market

52W Range Position

98%

Near high

Near its 52-week high

Technical Snapshot

SMA 20 / SMA 50

387.4 / 321.6

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

53.9

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹32 Cr	₹45 Cr	₹87 Cr	₹129 Cr	+59.7%
EBITDA	₹8 Cr	₹11 Cr	₹19 Cr	₹34 Cr	+64.8%
EBITDA Margin	24.0%	24.3%	21.6%	26.4%	—
PAT (Net Profit)	₹6 Cr	₹6 Cr	₹12 Cr	₹19 Cr	+46.8%
EPS	₹6.22	₹5.52	₹10.22	₹16.32	+37.9%
ROE	13.2%	12.0%	18.2%	19.0%	—
ROCE	13.6%	13.9%	17.0%	21.8%	—
Total Debt	₹8 Cr	₹18 Cr	₹54 Cr	₹73 Cr	+111.7%
Free Cash Flow	-₹26 Cr	-₹16 Cr	-₹15 Cr	-₹32 Cr	—

🟢 Revenue has grown at 59.7% a year over 3 years.

🟢 EBITDA has grown at 64.8% a year over 3 years.

🟢 EBITDA Margin has risen from 24.0% to 26.4% over 3 years (+2.4 pts).

🟢 PAT (Net Profit) has grown at 46.8% a year over 3 years.

🟢 EPS has grown at 37.9% a year over 3 years.

🟢 ROE has risen from 13.2% to 19.0% over 3 years (+5.8 pts).

🟢 ROCE has risen from 13.6% to 21.8% over 3 years (+8.2 pts).

🔴 Total Debt has grown at 111.7% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹237 Cr

Total Liabilities

₹129 Cr

Cash & Equivalents

₹4 Cr

Operating Cash Flow

₹5 Cr

Capex

-₹36 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

71.2%

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
DR. REDDY S LABORATORIES	31.0x	8.8%
CIPLA LTD	31.8x	9.8%
DIVI S LABORATORIES LTD	83.0x	17.5%

Recent News

3 mixed3 general

Trident Lifeline Issues 24,000 Equity Shares Via Warrant Conversion Raising ₹47.88 Lakh

Sahi, 17 OctFunding

🟡Mixed / dependsNew funding changes the capital structure. Debt raises leverage; an equity raise dilutes existing holders.

Trident Lifeline stake in subsidiary Mediquip falls to 58.23%

scanx.trade, 15 Oct

Trident Lifeline Ltd. Shareholding Pattern – Promoters, FIIs & DIIs

Value Research, 31 Aug

Trident Lifeline issues corrigendum to EGM notice for Oct 27 meeting

scanx.trade, 16 Oct

Trident Lifeline Share Price rises 9.09%: stock analysis

Univest, 25 SeptPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Trident Lifeline Share Price Rises 9.6% Today

Univest, 22 SeptPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Watch Items

Trading very close to its 52-week high — momentum-driven entries here carry more mean-reversion risk.
Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

StrongBusiness Quality · Profitability

MiddlingFinancial Health · Growth · Valuation · Risk

Points for each in the Score ↑

Attractive on both counts

A good business currently available at an undemanding price — the combination this framework exists to look for. The work left is qualitative: whether the advantage the numbers imply is one you can identify and expect to last. 4 high-severity red flags sit above this conclusion and should be read first.

2 of 5 tripwires tripped — Debt / EBITDA stays below 2x; Free cash flow remains positive · see Key things to watch ↑